Kyverna Therapeutics’ application for an Investigational New Drug has been cleared by the Food and Drug Administration. In early 2023, researchers will initiate a Phase 1 clinical trial of the investigational drug KYV-101 for the treatment of lupus kidney disease (lupus nephritis (LN)).

KYV-101 is another version of CAR-T experimental cell therapy that aims to eliminate B cells to reduce inflammation. B-cells are responsible for creating antibodies, including autoantibodies, and are thought to play a role in the development and progression of autoimmune diseases.

Continue to follow the Lupus Foundation of America for updates on KYV-101 and learn more about medications used to treat lupus.

Read the announcement